anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Optimal ribavirin dosages are essential in achieving SVR. The initial evidence supporting higher doses of ribavirin for peginterferon alfa-2b comes from a secondary analysis of the pivotal multicenter trial of peginterferon alfa-2b and ribavirin. Patients receiving more than 10.6 mg/kg/day ribavirin experienced significantly higher SVR rates (48% vs. 38%). A large multicenter trial designed to test standard dose ribavirin (1000-1200 mg/day) versus low-dose ribavirin (800 mg/day) in combination with peginterferon alfa-2a, showed 52% SVR in the standard dose group versus 41% in the low-dose group for genotype 1 infected patients. In the pooled data from two pivotal studies with peginterferon alfa-2a and ribavirin, the probability of achieving an SVR for genotype 1 patients was influenced by the ribavirin dose per kg body weight. A 40-50% increase in the probability of SVR was found for a 12-16 mg/kg dose increase of ribavirin. For peginterferon alfa-2b it was also shown among genotype 1 patients, that weight-based ribavirin (800-1400 mg/day) leads to higher SVR rates compared to fixed dose ribavirin (800 mg/day) (34% vs. 29%). Moreover, ribavirin dosing up to 1400 mg/day was safe and the rate of treatment discontinuation was the same for both treatment groups. In a small pilot study, 10 genotype 1 patients with a high baseline load were treated with peginterferon alfa-2a and individualized high-dose ribavirin in order to achieve a ribavirin target concentration in serum of 15 μmol/l. The mean ribavirin dose of 2540 mg/day (range 1600-3600 mg/day) was high, but resulted in 90% SVR. All patients experienced severe anemia, which was treated with concomitant epoetin beta and blood transfusion.

As mentioned before, the main concern of high-dose ribavirin will be a dose-dependent hemolytic anemia and the addition of epoetin alfa has shown significant increase of haemoglobin during (peg)interferon/ribavirin therapy. Erythropoietin doses from 9,000 to 60,000 IU/week have been used in order keep the highest possible ribavirin doses. A recent trial showed a significant higher SVR rate in genotype 1 patients treated with peginterferon alfa-2b, increased dose ribavirin (15.2 mg/kg/day) and epoetin alfa than in patients treated with peginterferon alfa-2b and standard dose ribavirin (13.3 mg/kg/day) with or without epoetin alfa. Using the standard ribavirin dose, routine use of erythropoietin significantly decreased the frequency of anemia and the mean ribavirin dose reduction. Moreover, with the addition of erythropoietin, a significant higher mean dose could be given to patients in the increased ribavirin dose arm.
Techniques are described herein for automatically verifying medical provider data. A service provider may receive medical provider data from one or more data sources. The data sources may include websites associated with health care services, search engines, crowd-sourced reviews, insurance claims from medical providers, feedback from patients (e.g., members), and the like. The service provider may compare the received medical provider data to stored medical provider data in a datastore, such as that stored in a medical provider account. The service provider may determine a probability that the stored medical provider data is accurate. Based on a determination that the probability is above a threshold, the service provider may automatically verify the stored medical provider data. Based on a determination that the probability is below the threshold, the service provider may request manual verification of the stored medical provider data.
PURPOSE:To provide a new aromatic compound having a 1-hydroxyimino-4- nitroolefin part, exhibiting an angiectactic effect, excellent in oral absorption and effective as a medicine for improving angina, cardiac failure, etc. CONSTITUTION:A compound [e.g. 2-(3-ethyl-1,3-pentenedienyl)-1- methoxymethylimidazole] represented by formula I [P is a group of formula II (a is NH, O or S; b, c and d are each CH or N; R<1> and R<2> are each H, a lower alkyl, a halogen, nitro, etc.), formula III, etc.; R<5> to R<8> are each H or a lower alkyl] is dissolved in a 40% aqueous methanol solution and pH is adjusted to 3 by adding an aqueous hydrochloric acid solution thereto. After adding sodium nitrite and reacting the resultant solution at room temperatures for 2hr, the reaction solution is extracted with ethyl acetate. The solvent is distilled off under vacuum from the organic layer and the residue is purified by the silica gel column chromatography, thus affording the aromatic compound (salt) represented by formula IV and exhibiting an angiectactic effect.
PURPOSE: To define the time to achievement of clinically significant outcomes (CSOs) after primary gluteus medius and/or minimus (GM) repair and to identify factors associated with delayed CSO achievement.
METHODS: Patients who underwent primary GM repair between January 2012 and June 2021 with complete preoperative, 6-month, 1-year, and 2-year Hip Outcome Score-Activities of Daily Living (HOS-ADL) were retrospectively identified. Cohort-specific minimal clinically important difference (MCID) and patient acceptable symptom state (PASS) were calculated. The time to achievement of MCID and PASS was analyzed using Kaplan-Meier survival analysis. Median time to MCID and PASS achievement was recorded. Multivariate stepwise Cox regressions were used to identify factors associated with delayed CSO achievement.
RESULTS: Fifty GM repairs were identified (age 59.4 ± 9.7 years, body mass index 27.9 ± 6.2, 94% female). Tears were grade 1 in 39 cases, grade 2 in 7 cases, and grade 3 in 4 cases. Endoscopic repair was performed in 35 cases, and open repair was performed in 15 cases. Labral debridement and repair were each performed in 15 cases. Median time to CSO achievement was 5.7 months for MCID and 11.0 months for PASS. The 2-year cumulative probability of MCID and PASS achievement was 92.7% and 66.7%, respectively. Preoperative hip abduction weakness on physical examination was associated with delayed achievement of MCID (hazard ratio 2.27, confidence interval 1.067-7.41, P = .039) and PASS (hazard ratio 3.89, confidence interval 1.341-11.283, P = .012).
CONCLUSIONS: This study demonstrated that in patients undergoing repair of primarily grade 1 GM tears, most achieved MCID by 6 months, and more than one half achieved PASS by 12 months. Preoperative hip abduction weakness on physical examination was associated with delayed CSO achievement.
LEVEL OF EVIDENCE: Level IV, retrospective case series.
LUMRYZ is a central nervous system (CNS) depressant. Clinically significant respiratory depression and obtundation has occurred in patients treated with immediate-release sodium oxybate at recommended doses in clinical trials and may occur in patients treated with LUMRYZ at recommended doses. LUMRYZ is contraindicated in combination with alcohol and sedative hypnotics. The concurrent use of LUMRYZ with other CNS depressants, including but not limited to opioid analgesics, benzodiazepines, sedating antidepressants or antipsychotics, sedating antiepileptic drugs, general anesthetics, muscle relaxants, and/or illicit CNS depressants, may increase the risk of respiratory depression, hypotension, profound sedation, syncope, and death. If use of these CNS depressants in combination with LUMRYZ is required, dose reduction or discontinuation of one or more CNS depressants (including LUMRYZ) should be considered. In addition, if short-term use of an opioid (e.g., post- or perioperative) is required, interruption of treatment with LUMRYZ should be considered. In addition to coadministration of LUMRYZ and alcohol being contraindicated because of respiratory depression, consumption of alcohol while taking LUMRYZ may also result in a more rapid release of the dose of sodium oxybate [see Clinical Pharmacology (12.3)].

Healthcare providers should caution patients about operating hazardous machinery, including automobiles or airplanes, until they are reasonably certain that LUMRYZ does not affect them adversely (e.g., impair judgment, thinking, or motor skills). Patients should not engage in hazardous occupations or activities requiring complete mental alertness or motor coordination, such as operating machinery or a motor vehicle or flying an airplane, for at least 6 hours after taking LUMRYZ. Patients should be queried about CNS depression-related events upon initiation of LUMRYZ therapy and periodically thereafter.

LUMRYZ is available only through a restricted program under a REMS [see Warnings and Precautions (5.3)].
FIELD: medicine, phytotherapy. SUBSTANCE: invention relates to the development of medicinal agents of natural origin. Invention proposes agent eliciting immunostimulating and anti-inflammatory effect comprising medicinal plants en-di, to-kal, khuangan, khuangi, tangu, penny-cross taken in equal ratio and snowdon rose and fisokhlen spirituous extracts and honey also. Invention proposes also method for preparing agent eliciting immunostimulating and anti- inflammatory effect that involves treatment of milled medicinal plants en-di, to-kal, khuangan, khuangi, tangu and penny-cross taken in equal ratio with steam for 15-20 min. Then mixture is kept, snowdon rose and fisokhlen spirituous extracts and honey are added to paste-like state being mixture of medicinal plants is kept for 3 days after its treatment with steam. Agent enhances immunoprotective body forces, improves microcirculation that promotes to prevention of development of cardiovascular diseases, enhances metabolic processes and shows an anti-inflammatory effect. EFFECT: improved preparing method, enhanced and valuable medicinal properties of agent. 3 cl, 2 ex
Corn leaf aphids (Rhopalosiphum maidis) are highly destructive pests of maize (Zea mays) that threaten growth and seed yield, but resources for aphid resistance are scarce. Here, we identified an aphid-resistant maize mutant, resistance to aphids 1 (rta1), which is allelic to LIGULELESS1 (LG1). We confirmed LG1's role in aphid resistance using the independent allele lg1-2, allelism tests and LG1 overexpression lines. LG1 interacts with, and increases the stability of ZINC-FINGER PROTEIN EXPRESSED IN INFLORESCENCE MERISTEM (ZIM1), a central component of the jasmonic acid (JA) signalling pathway, by disturbing its interaction with the F-box protein CORONATINE INSENSITIVE 1a (COI1a). Natural variation in the LG1 promoter was associated with aphid resistance among inbred lines. Moreover, a loss-of-function mutant in the LG1-related gene SPL8 in the dicot Arabidopsis thaliana conferred aphid resistance. This study revealed the aphid resistance mechanism of lg1, providing a theoretical basis and germplasm for breeding aphid-resistant crops.
PURPOSE:To obtain a polypeptide substantially having no exothermic action on mammals without damaging IL-1 activity, by treating human IL-1 with an enzyme. CONSTITUTION:IL-1 cDNA derived from human peripheral blood macrophage is cloned in Escherichia coli and the whole base sequence is determined. Then IL-1 manifestation plasmid is prepared from the IL-1 cDNA thereof and the cloned Escherichia coli is cultivated to give produce IL-1. The IL-1 is purified in high purity and then decomposed with an enzyme. Achromobacter Protease I or Staphylococcus aureus V8 Protease is used as the enzyme. Consequently, the desired polypeptide is obtained.
In cohorts 1-6, 8 subjects will be enrolled. 6 subjects will receive matching placebo.
Participants with progressed, metastatic prostate cancer who had received prior treatment with a docetaxel-containing agent. Participants were given 1125 mg loading dose of enzastaurin on Day 1 of Cycle 1 (28-day cycle) only, and thereafter 500 mg enzastaurin once daily.
While the cause of MS in not known, there is an autoimmune component that destroys nerve cells. Autoimmunity is a condition where an individual's immune system attacks his/her own cells. Bone marrow stem cell transplantation has been shown to halt autoimmunity. Stem cell transplant can be performed using the patient's own cells, or donor cells. The general consensus in the field is that donor transplant is most likely to halt disease progression. This study is designed to evaluate the safety of a donor transplant procedure as a therapy for relapsing remitting multiple sclerosis (RRMS).

Two factors limit the widespread application of traditional donor stem cell transplant: 1) preparing the patient for transplant (conditioning); and 2) graft-versus-host disease (GVHD). Traditional conditioning destroys the recipient's immune system and requires that the marrow transplant be successful because the patient is unable to fight off infection if the donor cells do not survive. GVHD occurs when donor immune cells recognize the recipient's cells as foreign tissue and attack them. Severe GVHD can result in death. This study utilizes a new approach to conditioning which leaves the patient's immune system intact. The transplant product is depleted of GVHD-producing cells but retains tolerance-promoting cells, called facilitating cells, which are intended to ensure the donor and recipient cells coexists peacefully. The toxicity of conditioning and transplantation is significantly reduced. The end result is a marrow system that contains recipient and donor cells, a state called mixed chimerism.

In this study, we will determine the appropriate cell dose to safely establish mixed chimerism following partial conditioning in patients with RRMS. The study takes a gradual approach to increasing the cell dose to achieve mixed chimerism. Each patient will receive a cell dose one unit above the dose received by the most recent safely transplanted patient. We believe this study will provide a breakthrough in the treatment of MS. The goal of this study is to evaluate the potential of safely establishing mixed chimerism to interrupt the autoimmune process and end the devastating effects of MS.
BACKGROUND AND AIMS: This study aimed to explore potential hub genes and pathways of plaque vulnerability and to investigate possible therapeutic targets for acute coronary syndrome (ACS).
METHODS AND RESULTS: Four microarray datasets were downloaded from the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs), weighted gene coexpression networks (WGCNA) and immune cell infiltration analysis (IIA) were used to identify the genes for plaque vulnerability. Then, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment, Disease Ontology, Gene Ontology annotation and protein-protein interaction (PPI) network analyses were performed to explore the hub genes. Random forest and artificial neural networks were constructed for validation. Furthermore, the CMap and Herb databases were employed to explore possible therapeutic targets. A total of 168 DEGs with an adjusted P < 0.05 and approximately 1974 IIA genes were identified in GSE62646. Three modules were detected and associated with CAD-Class, including 891 genes that can be found in GSE90074. After removing duplicates, 114 hub genes were used for functional analysis. GO functions identified 157 items, and 6 pathways were enriched for the KEGG pathway at adjusted P < 0.05 (false discovery rate, FDR set at < 0.05). Random forest and artificial neural network models were built based on the GSE48060 and GSE34822 datasets, respectively, to validate the previous hub genes. Five genes (GZMA, GZMB, KLRB1, KLRD1 and TRPM6) were selected, and only two of them (GZMA and GZMB) were screened as therapeutic targets in the CMap and Herb databases.
CONCLUSION: We performed a comprehensive analysis and validated GZMA and GZMB as a target for plaque vulnerability, which provides a therapeutic strategy for the prevention of ACS. However, whether it can be used as a predictor in blood samples requires further experimental verification.
Several neurodegenerative diseases, such as multiple sclerosis and Parkinson's disease, are linked to alterations in myelin content or structure. Transmembrane receptors such as integrins could be involved in these alterations. In the present study, we investigated the role of αv-integrins in experimental models of neuroinflammation and demyelination with the use of lebecetin (LCT), a C-lectin protein purified from Macrovipera lebetina viper venom, as an αv-integrin modulator. In a model of neuroinflammation, LCT inhibited the upregulation of αv, β3, β5, α5, and β1 integrins, as well as the associated release of pro-inflammatory factor IL-6 and chemokine CXCL-10, and decreased the expression of phosphorylated NfκB. The subsequent "indirect culture" between reactive astrocytes and oligodendrocytes showed a down-regulation of αv and β3 integrins versus upregulation of β1 one, accompanied by a reduced expression of myelin basic protein (MBP). Treatment of oligodendrocytes with LCT rectified the changes in integrin and MBP expression. Through Western blot quantification, LCT was shown to upregulate the expression levels of PI3K and p-mTOR while downregulating expression levels of p-AKT in oligodendrocytes, suggesting the neuroprotective and pro-myelinating effects of LCT may be related to the PI3K/mTor/AKT pathway. Concomitantly, we found that LCT promoted remyelination by tracking the increased expression of MBP in the brains of cuprizone-intoxicated mice. These results point to an involvement of integrins in not only neuroinflammation but demyelination as well. Thus, targeting αv integrins could offer potential therapeutic avenues for the treatment of demyelinating diseases.
The gut microbiome (GM) modulates body weight/composition and gastrointestinal functioning; therefore, approaches targeting resident gut microbes have attracted considerable interest. Intermittent fasting (IF) and protein pacing (P) regimens are effective in facilitating weight loss (WL) and enhancing body composition. However, the interrelationships between IF- and P-induced WL and the GM are unknown. The current randomized controlled study describes distinct fecal microbial and plasma metabolomic signatures between combined IF-P (n = 21) versus a heart-healthy, calorie-restricted (CR, n = 20) diet matched for overall energy intake in free-living human participants (women = 27; men = 14) with overweight/obesity for 8 weeks. Gut symptomatology improves and abundance of Christensenellaceae microbes and circulating cytokines and amino acid metabolites favoring fat oxidation increase with IF-P (p < 0.05), whereas metabolites associated with a longevity-related metabolic pathway increase with CR (p < 0.05). Differences indicate GM and metabolomic factors play a role in WL maintenance and body composition. This novel work provides insight into the GM and metabolomic profile of participants following an IF-P or CR diet and highlights important differences in microbial assembly associated with WL and body composition responsiveness. These data may inform future GM-focused precision nutrition recommendations using larger sample sizes of longer duration. Trial registration, March 6, 2020 (ClinicalTrials.gov as NCT04327141), based on a previous randomized intervention trial.
Dutasteride, USP is a synthetic 4-azasteroid compound that is a selective inhibitor of both the type 1 and type 2 isoforms of steroid 5 alpha-reductase, an intracellular enzyme that converts testosterone to DHT. 

Dutasteride is chemically designated as (5α,17β)-N-{2,5 bis(trifluoromethyl)phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide. The molecular formula of dutasteride is C27H30F6N2O2, representing a molecular weight of 528.5 with the following structural formula: 

Dutasteride, USP is white to pale yellow colored powder. It is soluble in ethanol and methanol, slightly soluble in polyethylene glycol 400 and insoluble in water.

Each dutasteride capsules intended for oral administration contains 0.5 mg of dutasteride dissolved in a mixture of mono and diglycerides of caprylic/capric acid and butylated hydroxytoluene. In addition, each capsule contains the following inactive ingredients: butylated hydroxy toluene, gelatin, glycerin, methylparaben, mono and diglycerides, propylparaben and titanium dioxide. The capsule is printed with black pharmaceutical ink which contains alcohol, ammonium hydroxide, ferric oxide black, isopropyl alcohol, polyethylene glycol, polyvinyl acetate phthalate, propylene glycol and purified water.
Variables related to socioeconomic status (SES), including income, ethnicity, and education, shape contact structures and affect the spread of infectious diseases. However, these factors are often overlooked in epidemic models, which typically stratify social contacts by age and interaction contexts. Here, we introduce and study generalized contact matrices that stratify contacts across multiple dimensions. We demonstrate a lower-bound theorem proving that disregarding additional dimensions, besides age and context, might lead to an underestimation of the basic reproductive number. By using SES variables in both synthetic and empirical data, we illustrate how generalized contact matrices enhance epidemic models, capturing variations in behaviors such as heterogeneous levels of adherence to nonpharmaceutical interventions among demographic groups. Moreover, we highlight the importance of integrating SES traits into epidemic models, as neglecting them might lead to substantial misrepresentation of epidemic outcomes and dynamics. Our research contributes to the efforts aiming at incorporating socioeconomic and other dimensions into epidemic modeling.
FIELD: biotechnology. SUBSTANCE: strain Proteus mirabilis N 2536 is isolated from patient with urological infection in 1992 and deposited in Collection of The State Scientific-Research Institute of standardization and control of medicinal biological preparation at number 237. Genetic properties of the strain: strain shows resistance to penicillin, neomycin, monomycin, polymyxin, tetracycline, lyncomycin, erythromycin, ristomycin, oxacilline, levomycetin. Strain shows increased toxin-producing capability. Strain can be used for preparing thermolabile enterotoxin and anatoxin from Proteus mirabilis at vaccines production. EFFECT: new strain indicated above, increased production of toxins. 1 tbl
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention describes the novel compounds of the formula (I)   where R 1  and R 2  are hydrogen atoms or R 1  is hydrogen atom and R 2  is hydroxyl group or OR 1  and R 2  in common form cyclic carbonate group of the formula:  ; R 3  can be α- or β-oriented and means hydrogen atom or alkylsilyl-group but triethylsilyl is preferable; R 4  is hydrogen atom or residue   or isoserine residue of the formula (A)   where   is direct or branched alkyl-group containing one-five carbon atoms;   is direct or branched alkyl group containing one-five carbon atoms or tert.-butoxyl-group at condition that when R 2  is H then R 4  is distinct from H and isoserine residue of the formula (A). Compounds show anticarcinogenic effect with respect to different human tumor forms. Invention describes also method of their synthesis, intermediate compounds and pharmaceutical composition based on the above indicated compounds. Pharmaceutical composition can be administrated by injection or oral route. EFFECT: higher antitumor properties. 8 cl, 2 tbl